---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-25-000091"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:33:30.119917+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics Q2 net loss $6.4M; cash runway into Q4 2025; SER-252 on track for clinic this year

## Summary
- Net loss $6.4M ($0.66/share) vs prior-year net income $5.2M ($0.61/share).
- Revenue $130k (NIH grants) vs $51k YoY; R&D spend up 100% to $3.2M.
- Cash $6.0M; projects funding into Q4 2025; raised $1.2M net via ATM at avg $5.95.
- Lead candidate SER-252 (POZ-apomorphine) on track for Phase 1 in Q4 2025.
- Advanced SER-270 (once-weekly injectable) for tardive dyskinesia; appointed Dr. Brannan to board.

## SEC filing metadata
- accession: 0001708599-25-000091
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000091/0001708599-25-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000091/ser-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-25-000091
- JSON: https://secwatch.observer/filing/0001708599-25-000091.json
- Plain text: https://secwatch.observer/filing/0001708599-25-000091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.